IL7R (P16871) variants and mutations
IL7R (also known as P16871) is a human protein-coding gene encoding an interleukin-7 receptor subunit alpha protein. It transmits survival and developmental signals required for T-cell and lymphoid homeostasis. Biallelic loss-of-function variants cause T-cell-negative, B-cell-positive severe combined immunodeficiency, while somatic activating alterations occur in acute lymphoblastic leukemia. This analysis covers 1,622 IL7R variants and mutations. Of these, 50% have computational variant effect predictions. Disease context includes immunodeficiency 104, asthma, and multiple sclerosis. Example IL7R variants include M1R, T2A, and T2I.
Variant analysis overview
- Gene: IL7R
- Protein: P16871
- UniProt accession: P16871
- Organism: Homo sapiens
- Variants analyzed: 1622
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,423 unspecified-consequence records; 87 missense variants; 81 synonymous variants; 22 frameshift variants; 5 stop-gained variants; 1 splice-region variants; 2 stop lost; 1 stop retained variant
- Prediction scores: 807 variants have prediction scores (50% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 104, asthma, multiple sclerosis, T-B+ severe combined immunodeficiency due to JAK3 deficiency, hypothyroidism, Omenn syndrome, allergic rhinitis, atopic eczema, Eczematoid dermatitis, primary biliary cholangitis, allergic disease, dermatitis.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 7 post-translational modification sites.
- Structural context: 376 variants have structural context.
- PTM context: 15 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IL7R variants
Examples include M1R, T2A, T2I, T2K, T2T, I3V, L4P, L4R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1R (p.Met1Arg), rs200076125, ClinGen CA3231813, ClinVar RCV001219210, ClinVar RCV004768927, MetaLR 0.56, MetaSVM 0.29, Likely pathogenic, Immunodeficiency 104; not provided; Severe combined immunodeficiency disease
- T2A (p.Thr2Ala), Ensembl rs1759658158, REVEL 0.28, CADD 25.20
- T2I (p.Thr2Ile), gnomAD 5-35856982-C-T, REVEL 0.33, CADD 20.70
- T2K (p.Thr2Lys), gnomAD 5-35856982-C-A, REVEL 0.36, CADD 23.00
- T2T (p.Thr2Thr), gnomAD 5-35856983-A-G, CADD 11.10
- I3V (p.Ile3Val), gnomAD rs1193803606, REVEL 0.16, CADD 13.10
- L4P (p.Leu4Pro), rs1759658576, NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, ClinGen CA359425625, AlphaMissense 0.28, MetaLR 0.59, Uncertain significance, Immunodeficiency 104
- L4R (p.Leu4Arg), Ensembl rs1759658576
- L4I (p.Leu4Ile), gnomAD 5-35856987-C-A, REVEL 0.31, CADD 23.60
- L4L (p.Leu4Leu), gnomAD 5-35856989-A-G, CADD 12.30
- G5C (p.Gly5Cys), rs1374760636, NCI-TCGA Cosmic COSV5741, cosmic curated COSV57411, gnomAD rs1374760636, REVEL 0.32, CADD 19.90, Variant assessed as somatic; moderate impact.
- G5D (p.Gly5Asp), cosmic curated COSV10514, TOPMed rs1759658878, gnomAD rs1759658878, REVEL 0.36, CADD 24.20
- G5S (p.Gly5Ser), gnomAD rs1374760636, REVEL 0.09, CADD 14.30
- G5V (p.Gly5Val), gnomAD 5-35856991-G-T, REVEL 0.39, CADD 24.20
- T6A (p.Thr6Ala), rs1580848036, ClinGen CA359425654, ClinVar RCV001372925, Ensembl rs1580848036, AlphaMissense 0.08, MetaLR 0.35, Uncertain significance, Immunodeficiency 104
- T6I (p.Thr6Ile), ExAC rs771047572, TOPMed rs771047572, gnomAD rs771047572, REVEL 0.16, CADD 10.20
- T6K (p.Thr6Lys), ExAC rs771047572, TOPMed rs771047572, gnomAD rs771047572, REVEL 0.36, CADD 10.90
- T6T (p.Thr6Thr), gnomAD 5-35856995-A-G, CADD 8.76
- T7I (p.Thr7Ile), rs1162451134, ClinGen CA359425714, ClinVar RCV003374096, gnomAD rs1162451134, AlphaMissense 0.09, MetaLR 0.30, Uncertain significance, Inborn genetic diseases
- T7N (p.Thr7Asn), gnomAD rs1162451134, REVEL 0.28, AlphaMissense 0.09, Uncertain significance
- T7T (p.Thr7Thr), gnomAD 5-35856998-T-C, CADD 9.47
- F8L (p.Phe8Leu), gnomAD 5-35856997-CT-C, CADD 21.60
- F8F (p.Phe8Phe), gnomAD 5-35857001-T-C, CADD 8.71
- G9A (p.Gly9Ala), rs776642878, ClinGen CA3231815, ClinVar RCV002611780, ExAC rs776642878, REVEL 0.09, CADD 13.50, Uncertain significance, Immunodeficiency 104
- G9D (p.Gly9Asp), ExAC rs776642878, gnomAD rs776642878, Uncertain significance
- G9S (p.Gly9Ser), gnomAD 5-35857002-G-A, REVEL 0.17, CADD 22.10
- G9C (p.Gly9Cys), gnomAD 5-35857002-G-T, REVEL 0.32, CADD 26.30
- G9V (p.Gly9Val), gnomAD 5-35857003-G-T, REVEL 0.37, CADD 22.90
- G9G (p.Gly9Gly), rs770050857, gnomAD 5-35857004-C-T, CADD 7.58
- M10I (p.Met10Ile), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Variant assessed as somatic; moderate impact.
- M10V (p.Met10Val), ESP rs145097494, ExAC rs145097494, TOPMed rs145097494, gnomAD rs145097494, REVEL 0.14, CADD 0.70
- M10T (p.Met10Thr), gnomAD 5-35857006-T-C, REVEL 0.13, CADD 7.30
- V11A (p.Val11Ala), rs539820821, ClinGen CA3231819, ClinVar RCV001235068, 1000Genomes rs539820821, REVEL 0.14, AlphaMissense 0.11, Uncertain significance, Immunodeficiency 104
- V11F (p.Val11Phe), cosmic curated COSV10731, TOPMed rs1759660556, gnomAD rs1759660556, REVEL 0.33, CADD 1.36
- V11G (p.Val11Gly), rs539820821, ClinGen CA359425803, ClinVar RCV003020175, AlphaMissense 0.11, MetaLR 0.18, Uncertain significance, Immunodeficiency 104
- V11I (p.Val11Ile), cosmic curated COSV57413, TOPMed rs1759660556, gnomAD rs1759660556, REVEL 0.10, CADD 0.14
- V11D (p.Val11Asp), gnomAD 5-35857009-T-A, REVEL 0.46, CADD 22.80
- F12I (p.Phe12Ile), NCI-TCGA Cosmic COSV5740, cosmic curated COSV57407, Variant assessed as somatic; moderate impact.
- F12L (p.Phe12Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F12F (p.Phe12Phe), gnomAD 5-35857013-T-C, CADD 12.70
- S13C (p.Ser13Cys), NCI-TCGA Cosmic COSV1002, NCI-TCGA Cosmic COSV5741, cosmic curated COSV57411, REVEL 0.20, CADD 14.30, Variant assessed as somatic; moderate impact.
- S13F (p.Ser13Phe), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, NCI-TCGA Cosmic COSV5741, Variant assessed as somatic; moderate impact.
- S13L (p.Ser13Leu), rs1759660930, gnomAD 5-35857008-GT-G, CADD 22.10
- L14S (p.Leu14Ser), rs1759661333, ClinGen CA359425853, ClinVar RCV002244108, Ensembl rs1759661333, REVEL 0.63, CADD 27.10, Uncertain significance, Immunodeficiency 104
- L14V (p.Leu14Val), Ensembl rs1759661194
- L15F (p.Leu15Phe), TOPMed rs1759661468
- L15I (p.Leu15Ile), gnomAD 5-35857020-C-A, REVEL 0.07, CADD 19.20
- Q16E (p.Gln16Glu), TOPMed rs950299369, REVEL 0.23, CADD 22.10
- Q16H (p.Gln16His), gnomAD rs1387984147, REVEL 0.11, CADD 13.70
- Q16L (p.Gln16Leu), Ensembl rs1759661871
- Q16* (p.Gln16Ter), gnomAD 5-35857023-C-T, CADD 37.00
- Q16Q (p.Gln16Gln), rs1387984147, gnomAD 5-35857025-A-G, CADD 11.20
- V17F (p.Val17Phe), gnomAD 5-35857026-G-T, REVEL 0.28, CADD 23.20
- V17V (p.Val17Val), rs138981776, gnomAD 5-35857028-C-T, CADD 7.24
- V18A (p.Val18Ala), rs1472882776, ClinGen CA359425974, ClinVar RCV001953185, TOPMed rs1472882776, REVEL 0.14, CADD 19.20, Uncertain significance, Immunodeficiency 104
- V18I (p.Val18Ile), cosmic curated COSV10514, TOPMed rs1320815333, gnomAD rs1320815333, REVEL 0.21, CADD 22.90
- V18L (p.Val18Leu), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Variant assessed as somatic; moderate impact.
- S19Y (p.Ser19Tyr), gnomAD rs1339277801, REVEL 0.44, CADD 24.20
- S19A (p.Ser19Ala), gnomAD 5-35857032-T-G, REVEL 0.32, CADD 23.20
- G20* (p.Gly20Ter), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Variant assessed as somatic; high impact.
- G20E (p.Gly20Glu), rs1759663249, ClinGen CA359426038, ClinVar RCV001223735, ClinVar RCV002562586, REVEL 0.70, CADD 26.80, Uncertain significance, Immunodeficiency 104; Inborn genetic diseases
- G20R (p.Gly20Arg), gnomAD 5-35857035-G-A, REVEL 0.70, CADD 32.00
- G20A (p.Gly20Ala), gnomAD 5-35857036-G-C, REVEL 0.58, CADD 26.30
- G20G (p.Gly20Gly), rs780995324, gnomAD 5-35857037-A-T, CADD 15.30
- E21* (p.Glu21Ter), gnomAD 5-35857038-G-T, CADD 37.00
- E21K (p.Glu21Lys), gnomAD 5-35857038-G-A, REVEL 0.55, CADD 27.50
- S22R (p.Ser22Arg), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, gnomAD rs1165388643, Likely benign
- S22G (p.Ser22Gly), gnomAD 5-35857041-A-G, REVEL 0.51, CADD 26.80
- S22I (p.Ser22Ile), gnomAD 5-35857042-G-T, REVEL 0.63, CADD 27.90
- S22S (p.Ser22Ser), rs1165388643, gnomAD 5-35857043-T-C, CADD 14.20
- G23A (p.Gly23Ala), ExAC rs760033705, gnomAD rs760033705, REVEL 0.54, CADD 26.50
- G23S (p.Gly23Ser), gnomAD 5-35857044-G-A, REVEL 0.50, CADD 29.40
- G23C (p.Gly23Cys), gnomAD 5-35857044-G-T, REVEL 0.62, CADD 29.70
- G23G (p.Gly23Gly), gnomAD 5-35857046-C-G, CADD 14.50
- Y24N (p.Tyr24Asn), gnomAD 5-35857047-T-A, REVEL 0.16, CADD 20.40
- Y24H (p.Tyr24His), gnomAD 5-35857047-T-C, REVEL 0.20, CADD 19.20
- Y24C (p.Tyr24Cys), gnomAD 5-35857048-A-G, REVEL 0.21, CADD 22.90
- A25P (p.Ala25Pro), Ensembl rs922409337
- A25S (p.Ala25Ser), Ensembl rs922409337, REVEL 0.16, CADD 23.50
- A25T (p.Ala25Thr), Ensembl rs922409337, REVEL 0.14, CADD 22.60
- A25D (p.Ala25Asp), gnomAD 5-35857051-C-A, REVEL 0.36, CADD 22.90
- A25V (p.Ala25Val), gnomAD 5-35857051-C-T, REVEL 0.20, CADD 22.70
- A25A (p.Ala25Ala), rs2149893544, gnomAD 5-35857052-T-A, CADD 4.77
- Q26* (p.Gln26Ter), rs202007062, ClinGen CA3231823, cosmic curated COSV10514, ClinVar RCV003516297, CADD 36.00, Pathogenic
- Q26K (p.Gln26Lys), ExAC rs202007062, TOPMed rs202007062, gnomAD rs202007062, REVEL 0.08, CADD 19.90, Pathogenic
- Q26R (p.Gln26Arg), gnomAD 5-35857054-A-G, REVEL 0.21, CADD 23.60
- Q26Q (p.Gln26Gln), gnomAD 5-35857055-A-G, CADD 11.60
- N27H (p.Asn27His), TOPMed rs1208455689, gnomAD rs1208455689, REVEL 0.21, CADD 24.40
- N27K (p.Asn27Lys), rs753451294, ClinGen CA3231824, ClinVar RCV000640057, ExAC rs753451294, REVEL 0.18, CADD 23.30, Uncertain significance, Immunodeficiency 104
- N27M (p.Asn27Met), gnomAD 5-35857053-CA-C, CADD 26.00
- N27N (p.Asn27Asn), rs753451294, gnomAD 5-35857058-T-C, CADD 14.20
- G28* (p.Gly28Ter), NCI-TCGA Cosmic COSV5740, CADD 48.00, Variant assessed as somatic; high impact.
- G28R (p.Gly28Arg), gnomAD rs1234733163, NCI-TCGA Cosmic COSV5740, cosmic curated COSV57409, REVEL 0.64, CADD 34.00, Variant assessed as somatic; moderate impact.
- D29H (p.Asp29His), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, NCI-TCGA Cosmic COSV5740, Variant assessed as somatic; moderate impact.
- D29N (p.Asp29Asn), NCI-TCGA Cosmic COSV1002, NCI-TCGA Cosmic COSV5740, cosmic curated COSV57405, Variant assessed as somatic; moderate impact.
- D29Y (p.Asp29Tyr), NCI-TCGA Cosmic COSV1002, NCI-TCGA Cosmic COSV5740, Variant assessed as somatic; moderate impact.
- D29G (p.Asp29Gly), gnomAD 5-35860855-A-G, REVEL 0.31, CADD 22.80
- D29D (p.Asp29Asp), rs370292681, gnomAD 5-35860856-C-T, CADD 4.85
- D29E (p.Asp29Glu), gnomAD 5-35860856-C-G, REVEL 0.27, CADD 7.95
- L30S (p.Leu30Ser), Ensembl rs1759786831, REVEL 0.56, CADD 22.90
- D32N (p.Asp32Asn), cosmic curated COSV57413, Ensembl rs2149895596
- D32D (p.Asp32Asp), rs1391631391, gnomAD 5-35860865-T-C, CADD 4.75
- A33T (p.Ala33Thr), ESP rs140673282, ExAC rs140673282, TOPMed rs140673282, gnomAD rs140673282, REVEL 0.33, CADD 23.20
- A33V (p.Ala33Val), Ensembl rs2149895605
- A33A (p.Ala33Ala), rs992083666, gnomAD 5-35860868-A-G, CADD 1.64
- E34K (p.Glu34Lys), Ensembl rs2149895609
- E34Q (p.Glu34Gln), Ensembl rs2149895609
- E34V (p.Glu34Val), gnomAD 5-35860870-A-T, REVEL 0.45, CADD 27.30
- E34E (p.Glu34Glu), rs1036441865, gnomAD 5-35860871-A-G, CADD 3.04
- E34D (p.Glu34Asp), gnomAD 5-35860871-A-C, REVEL 0.29, CADD 16.90
- L35M (p.Leu35Met), rs752402991, ClinGen CA3231846, ClinVar RCV004405333, ExAC rs752402991, REVEL 0.17, CADD 10.20, Uncertain significance, Inborn genetic diseases
- L35Q (p.Leu35Gln), rs35967524, ClinGen CA3231847, ClinVar RCV001927514, ExAC rs35967524, REVEL 0.23, CADD 4.27, Uncertain significance, Immunodeficiency 104
- L35R (p.Leu35Arg), ExAC rs35967524, TOPMed rs35967524, gnomAD rs35967524, REVEL 0.26, CADD 5.96, Uncertain significance
- L35L (p.Leu35Leu), gnomAD 5-35860872-C-T, CADD 5.91
- D36N (p.Asp36Asn), cosmic curated COSV57407, TOPMed rs1177711424, REVEL 0.37, CADD 25.50
- D36G (p.Asp36Gly), gnomAD 5-35860876-A-G, REVEL 0.66, CADD 25.90
- D37E (p.Asp37Glu), ExAC rs763937095, TOPMed rs763937095, gnomAD rs763937095, Uncertain significance
- D37D (p.Asp37Asp), rs763937095, gnomAD 5-35860880-C-T, CADD 5.76
- Y38F (p.Tyr38Phe), ExAC rs751358220, gnomAD rs751358220, REVEL 0.04, CADD 13.80
- Y38N (p.Tyr38Asn), gnomAD 5-35860881-T-A, REVEL 0.34, CADD 22.90
- Y38Y (p.Tyr38Tyr), rs2149895624, gnomAD 5-35860883-C-T, CADD 5.85
- S39* (p.Ser39Ter), NCI-TCGA TCGA novel, Ensembl rs1759787685, Variant assessed as somatic; high impact.
- S39S (p.Ser39Ser), rs1349991152, gnomAD 5-35860886-A-T, CADD 0.59
- F40L (p.Phe40Leu), rs1759787978, ClinGen CA359426693, ClinVar RCV002260878, ClinVar RCV004820909, AlphaMissense 0.90, MetaLR 0.54, Uncertain significance
- F40S (p.Phe40Ser), NCI-TCGA Cosmic COSV5740, cosmic curated COSV57408, NCI-TCGA Cosmic COSV5741, Variant assessed as somatic; moderate impact.
- S41L (p.Ser41Leu), gnomAD rs1759788104, REVEL 0.32, CADD 24.80
- S41S (p.Ser41Ser), gnomAD 5-35860892-A-G, CADD 1.09
- C42S (p.Cys42Ser), Ensembl rs2149895633
- C42W (p.Cys42Trp), rs1759788196, ClinGen CA359426719, ClinVar RCV001998094, Ensembl rs1759788196, AlphaMissense 0.94, MetaLR 0.55, Pathogenic, Immunodeficiency 104
- C42Y (p.Cys42Tyr), cosmic curated COSV57410, Ensembl rs2149895633
- C42C (p.Cys42Cys), rs1759788196, gnomAD 5-35860895-C-T, AlphaMissense 0.94, MetaLR 0.55
- Y43C (p.Tyr43Cys), rs373694709, ClinGen CA3231850, ClinVar RCV002771394, ESP rs373694709, REVEL 0.40, CADD 24.20, Uncertain significance, Immunodeficiency 104
- Y43Y (p.Tyr43Tyr), rs1273666609, gnomAD 5-35860898-T-C, CADD 5.38
- S44C (p.Ser44Cys), Ensembl rs2149895643
- S44I (p.Ser44Ile), NCI-TCGA Cosmic COSV5741, cosmic curated COSV57410, REVEL 0.66, CADD 24.80, Variant assessed as somatic; moderate impact.
- S44R (p.Ser44Arg), 1000Genomes rs11567704, ESP rs11567704, ExAC rs11567704, TOPMed rs11567704, REVEL 0.64, CADD 22.80, Uncertain significance, not specified
- S44S (p.Ser44Ser), rs11567704, gnomAD 5-35860901-C-T, CADD 8.91
- Q45H (p.Gln45His), rs200464578, ClinGen CA359426752, ClinVar RCV001900777, Ensembl rs200464578, REVEL 0.63, CADD 24.90, Uncertain significance, Immunodeficiency 104
- Q45P (p.Gln45Pro), rs1561418803, ClinVar RCV000766122, TOPMed rs1561418803, AlphaMissense 0.63, MetaLR 0.59, no classification for the single variant, Immunodeficiency 104
- Q45R (p.Gln45Arg), gnomAD 5-35860903-A-G, REVEL 0.68, CADD 25.40
- Q45Q (p.Gln45Gln), rs200464578, gnomAD 5-35860904-G-A, CADD 9.02
- L46W (p.Leu46Trp), rs2531547515, ClinGen CA359426763, ClinVar RCV003990961, Uncertain significance, Immunodeficiency 104
- L46L (p.Leu46Leu), gnomAD 5-35860905-T-C, CADD 8.71
- E47K (p.Glu47Lys), cosmic curated COSV57405, Ensembl rs2149895654
- E47E (p.Glu47Glu), rs1561418812, gnomAD 5-35860910-A-G, CADD 8.35
- V48M (p.Val48Met), gnomAD 5-35860911-G-A, REVEL 0.37, CADD 25.80
- N49D (p.Asn49Asp), rs2531547543, ClinGen CA359426796, ClinVar RCV003514677, Uncertain significance, Immunodeficiency 104
- N49K (p.Asn49Lys), Ensembl rs1450512955
- N49S (p.Asn49Ser), Ensembl rs1759789214
- N49N (p.Asn49Asn), gnomAD 5-35860916-T-C, CADD 7.57
- G50E (p.Gly50Glu), cosmic curated COSV10814, NCI-TCGA TCGA novel, REVEL 0.45, CADD 23.40, Variant assessed as somatic; moderate impact.
- G50V (p.Gly50Val), rs202083738, ClinGen CA160087, ClinVar RCV000121211, ClinVar RCV001155103, REVEL 0.48, CADD 25.30, Uncertain significance, Immunodeficiency 104
- G50R (p.Gly50Arg), gnomAD 5-35860917-G-C, REVEL 0.47, CADD 24.00
- S51* (p.Ser51Ter), 1000Genomes rs138482569, ESP rs138482569, ExAC rs138482569, TOPMed rs138482569, Likely benign
- S51L (p.Ser51Leu), rs138482569, ClinGen CA160084, cosmic curated COSV57410, ClinVar RCV000121210, REVEL 0.18, CADD 12.00, Likely benign, Immunodeficiency 104
- S51T (p.Ser51Thr), gnomAD rs1265582612, REVEL 0.10, CADD 1.21
- S51W (p.Ser51Trp), 1000Genomes rs138482569, ESP rs138482569, ExAC rs138482569, TOPMed rs138482569, REVEL 0.35, CADD 21.20, Likely benign
- S51S (p.Ser51Ser), rs149235072, gnomAD 5-35860922-G-T, CADD 6.66
- Q52* (p.Gln52Ter), TOPMed rs1759790215, CADD 35.00
- Q52H (p.Gln52His), rs768814999, ClinGen CA3231854, ClinVar RCV002750014, ExAC rs768814999, REVEL 0.17, CADD 11.10, Uncertain significance, Inborn genetic diseases
- Q52T (p.Gln52Thr), gnomAD 5-35860917-GGATC-, CADD 26.60
- Q52Q (p.Gln52Gln), rs768814999, gnomAD 5-35860925-G-A, CADD 6.36
- H53Y (p.His53Tyr), rs779308643, ClinGen CA3231855, ClinVar RCV002750015, ExAC rs779308643, REVEL 0.45, CADD 23.70, Uncertain significance, Inborn genetic diseases
- H53P (p.His53Pro), gnomAD 5-35860927-A-C, REVEL 0.62, CADD 25.00
- S54L (p.Ser54Leu), NCI-TCGA Cosmic COSV5740, cosmic curated COSV57408, Variant assessed as somatic; moderate impact.
- S54P (p.Ser54Pro), rs1002396899, ClinVar RCV000766123, TOPMed rs1002396899, gnomAD rs1002396899, REVEL 0.43, CADD 19.20, no classification for the single variant, Immunodeficiency 104
- L55P (p.Leu55Pro), rs1273552553, ClinGen CA359426866, ClinVar RCV000810774, TOPMed rs1273552553, REVEL 0.70, CADD 25.00, Uncertain significance, Immunodeficiency 104
- L55R (p.Leu55Arg), TOPMed rs1273552553, gnomAD rs1273552553, Uncertain significance
- L55M (p.Leu55Met), gnomAD 5-35860932-C-A, REVEL 0.54, CADD 19.90
- L55L (p.Leu55Leu), rs748495760, gnomAD 5-35860934-G-A, CADD 8.06
- T56N (p.Thr56Asn), Ensembl rs2149895692
- T56P (p.Thr56Pro), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, NCI-TCGA Cosmic COSV5740, Variant assessed as somatic; moderate impact.
- T56S (p.Thr56Ser), NCI-TCGA Cosmic COSV1002, NCI-TCGA Cosmic COSV5740, cosmic curated COSV57409, Ensembl rs2149895686, Variant assessed as somatic; moderate impact.
- T56T (p.Thr56Thr), rs267600609, gnomAD 5-35860937-C-T, CADD 8.67
- C57R (p.Cys57Arg), rs1759791006, ClinGen CA359426883, ClinVar RCV001208645, Ensembl rs1759791006, AlphaMissense 0.95, MetaLR 0.54, Uncertain significance, Immunodeficiency 104
- C57Y (p.Cys57Tyr), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10028, Ensembl rs2149895703, Variant assessed as somatic; moderate impact.
- C57W (p.Cys57Trp), gnomAD 5-35860940-T-G, REVEL 0.73, CADD 24.60
- A58G (p.Ala58Gly), TOPMed rs1327554053, gnomAD rs1327554053
- A58V (p.Ala58Val), TOPMed rs1327554053, gnomAD rs1327554053, REVEL 0.16, CADD 19.30
- E60D (p.Glu60Asp), Ensembl rs2149895713
Public IL7R analysis runs
- IL7R analysis run — IL7R (1,622 variants) — completed 2026-08-19